A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$59.84
arrow_upward
+0.74%(+0.44) 1D
Oct 16, 10:56:22 AM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1LN34...
Open
R$59.28
High
R$59.84
Low
R$59.28
Mkt. cap
31.48B
Avg. vol.
446.00
Volume
17.00
52-wk high
R$131.80
52-wk low
R$50.25
Shares outstanding
133.81M
No. of employees
2K
Open
R$59.28
High
R$59.84
Low
R$59.28
Mkt. cap
31.48B
Avg. vol.
446.00
Volume
17.00
52-wk high
R$131.80
52-wk low
R$50.25
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
The Business Journals
·
1 hour ago
Alnylam founder's new biotech lands $200M in upsized IPO
ChartMill
·
3 hours ago
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum
ad-hoc-news.de
·
20 hours ago
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals Inc Bdr